REPORT ID 451

Asia-Pacific Candidiasis Therapeutics Market Report 2017

Publish Date
01-Dec-17
Pages
110
Format
Electronic (PDF)

In this report, the Asia-Pacific Candidiasis Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Candidiasis Therapeutics for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Candidiasis Therapeutics market competition by top manufacturers/players, with Candidiasis Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Novartis AG
    Amgen
    F. Hoffmann-La Roche Ltd.
    Bayer-Algeta
    Merrion Pharmaceuticals Plc.
    Ablynx
    Genta Incorporated
    Galapagos NV
    Catena Pharmaceuticals Inc.
    Digna Biotech S.L.
    Medivir AB
    Amura Holdings

On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
    Doxorubicin
    Cisplatin
    7Carboplatin
    Etoposide
    Ifosfamide
    Cyclophosphamide
    Methotrexate
    Vincristine

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Multispecialty Hospitals
    Cancer Research Institutes
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Candidiasis Therapeutics Market Report 2017
1 Candidiasis Therapeutics Overview
    1.1 Product Overview and Scope of Candidiasis Therapeutics
    1.2 Classification of Candidiasis Therapeutics by Product Category
        1.2.1 Asia-Pacific Candidiasis Therapeutics Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Candidiasis Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Doxorubicin
        1.2.4 Cisplatin
        1.2.5 7Carboplatin
        1.2.6 Etoposide
        1.2.7 Ifosfamide
        1.2.8 Cyclophosphamide
        1.2.9 Methotrexate
        1.2.10 Vincristine
    1.3 Asia-Pacific Candidiasis Therapeutics Market by Application/End Users
        1.3.1 Asia-Pacific Candidiasis Therapeutics Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Multispecialty Hospitals
        1.3.3 Cancer Research Institutes
        1.3.4 Others
    1.4 Asia-Pacific Candidiasis Therapeutics Market by Region
        1.4.1 Asia-Pacific Candidiasis Therapeutics Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Candidiasis Therapeutics (2012-2022)
        1.5.1 Asia-Pacific Candidiasis Therapeutics Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Candidiasis Therapeutics Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Candidiasis Therapeutics Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Candidiasis Therapeutics Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Candidiasis Therapeutics Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Candidiasis Therapeutics Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Candidiasis Therapeutics (Volume and Value) by Type
        2.2.1 Asia-Pacific Candidiasis Therapeutics Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Candidiasis Therapeutics Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Candidiasis Therapeutics (Volume) by Application
    2.4 Asia-Pacific Candidiasis Therapeutics (Volume and Value) by Region
        2.4.1 Asia-Pacific Candidiasis Therapeutics Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Candidiasis Therapeutics Revenue and Market Share by Region (2012-2017)

3 China Candidiasis Therapeutics (Volume, Value and Sales Price)
    3.1 China Candidiasis Therapeutics Sales and Value (2012-2017)
        3.1.1 China Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        3.1.3 China Candidiasis Therapeutics Sales Price Trend (2012-2017)
    3.2 China Candidiasis Therapeutics Sales Volume and Market Share by Type
    3.3 China Candidiasis Therapeutics Sales Volume and Market Share by Application

4 Japan Candidiasis Therapeutics (Volume, Value and Sales Price)
    4.1 Japan Candidiasis Therapeutics Sales and Value (2012-2017)
        4.1.1 Japan Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Candidiasis Therapeutics Sales Price Trend (2012-2017)
    4.2 Japan Candidiasis Therapeutics Sales Volume and Market Share by Type
    4.3 Japan Candidiasis Therapeutics Sales Volume and Market Share by Application

5 South Korea Candidiasis Therapeutics (Volume, Value and Sales Price)
    5.1 South Korea Candidiasis Therapeutics Sales and Value (2012-2017)
        5.1.1 South Korea Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Candidiasis Therapeutics Sales Price Trend (2012-2017)
    5.2 South Korea Candidiasis Therapeutics Sales Volume and Market Share by Type
    5.3 South Korea Candidiasis Therapeutics Sales Volume and Market Share by Application

6 Taiwan Candidiasis Therapeutics (Volume, Value and Sales Price)
    6.1 Taiwan Candidiasis Therapeutics Sales and Value (2012-2017)
        6.1.1 Taiwan Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Candidiasis Therapeutics Sales Price Trend (2012-2017)
    6.2 Taiwan Candidiasis Therapeutics Sales Volume and Market Share by Type
    6.3 Taiwan Candidiasis Therapeutics Sales Volume and Market Share by Application

7 India Candidiasis Therapeutics (Volume, Value and Sales Price)
    7.1 India Candidiasis Therapeutics Sales and Value (2012-2017)
        7.1.1 India Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        7.1.3 India Candidiasis Therapeutics Sales Price Trend (2012-2017)
    7.2 India Candidiasis Therapeutics Sales Volume and Market Share by Type
    7.3 India Candidiasis Therapeutics Sales Volume and Market Share by Application

8 Southeast Asia Candidiasis Therapeutics (Volume, Value and Sales Price)
    8.1 Southeast Asia Candidiasis Therapeutics Sales and Value (2012-2017)
        8.1.1 Southeast Asia Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Candidiasis Therapeutics Sales Price Trend (2012-2017)
    8.2 Southeast Asia Candidiasis Therapeutics Sales Volume and Market Share by Type
    8.3 Southeast Asia Candidiasis Therapeutics Sales Volume and Market Share by Application

9 Australia Candidiasis Therapeutics (Volume, Value and Sales Price)
    9.1 Australia Candidiasis Therapeutics Sales and Value (2012-2017)
        9.1.1 Australia Candidiasis Therapeutics Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Candidiasis Therapeutics Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Candidiasis Therapeutics Sales Price Trend (2012-2017)
    9.2 Australia Candidiasis Therapeutics Sales Volume and Market Share by Type
    9.3 Australia Candidiasis Therapeutics Sales Volume and Market Share by Application

10 Asia-Pacific Candidiasis Therapeutics Players/Suppliers Profiles and Sales Data
    10.1 Novartis AG
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 Novartis AG Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 Amgen
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 Amgen Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 F. Hoffmann-La Roche Ltd.
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    10.4 Bayer-Algeta
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 Bayer-Algeta Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.4.4 Main Business/Business Overview
    10.5 Merrion Pharmaceuticals Plc.
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.5.4 Main Business/Business Overview
    10.6 Ablynx
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 Ablynx Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.6.4 Main Business/Business Overview
    10.7 Genta Incorporated
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 Genta Incorporated Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.7.4 Main Business/Business Overview
    10.8 Galapagos NV
        10.8.1 Company Basic Information, Manufacturing Base and Competitors
        10.8.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.8.2.1 Product A
            10.8.2.2 Product B
        10.8.3 Galapagos NV Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.8.4 Main Business/Business Overview
    10.9 Catena Pharmaceuticals Inc.
        10.9.1 Company Basic Information, Manufacturing Base and Competitors
        10.9.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.9.2.1 Product A
            10.9.2.2 Product B
        10.9.3 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.9.4 Main Business/Business Overview
    10.10 Digna Biotech S.L.
        10.10.1 Company Basic Information, Manufacturing Base and Competitors
        10.10.2 Candidiasis Therapeutics Product Category, Application and Specification
            10.10.2.1 Product A
            10.10.2.2 Product B
        10.10.3 Digna Biotech S.L. Candidiasis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.10.4 Main Business/Business Overview
    10.11 Medivir AB
    10.12 Amura Holdings

11 Candidiasis Therapeutics Manufacturing Cost Analysis
    11.1 Candidiasis Therapeutics Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Candidiasis Therapeutics

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Candidiasis Therapeutics Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Candidiasis Therapeutics Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Candidiasis Therapeutics Market Forecast (2017-2022)
    15.1 Asia-Pacific Candidiasis Therapeutics Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Candidiasis Therapeutics Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Candidiasis Therapeutics Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Candidiasis Therapeutics Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific Candidiasis Therapeutics Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.1 Asia-Pacific Candidiasis Therapeutics Sales Volume and Growth Rate Forecast by Region (2017-2022)
        15.2.2 Asia-Pacific Candidiasis Therapeutics Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.3 China Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.4 Japan Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.5 South Korea Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.6 Taiwan Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.7 India Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.8 Southeast Asia Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.9 Australia Candidiasis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
    15.3 Asia-Pacific Candidiasis Therapeutics Sales, Revenue and Price Forecast by Type (2017-2022)
        15.3.1 Asia-Pacific Candidiasis Therapeutics Sales Forecast by Type (2017-2022)
        15.3.2 Asia-Pacific Candidiasis Therapeutics Revenue Forecast by Type (2017-2022)
        15.3.3 Asia-Pacific Candidiasis Therapeutics Price Forecast by Type (2017-2022)
    15.4 Asia-Pacific Candidiasis Therapeutics Sales Forecast by Application (2017-2022)

16 Research Findings and Conclusion

17 Appendix
    17.1 Methodology/Research Approach
        17.1.1 Research Programs/Design
        17.1.2 Market Size Estimation
        17.1.3 Market Breakdown and Data Triangulation
    17.2 Data Source
        17.2.1 Secondary Sources
        17.2.2 Primary Sources
    17.3 Disclaimer